Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria

Malaria, Vivax Clinical Trial

Official title:
Study 200894: A Double-blind, Double-dummy, Randomized, Parallel Group, Placebo-controlled Superiority Study to Evaluate the Efficacy and Safety of Tafenoquine (SB-252263, WR238605) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax Malaria

Status Completed

Clinical Trial Summary

Tafenoquine (TQ) is an 8-aminoquinoline anti-malarial drug which is in development as a single-dose treatment for the radical cure of P.vivax malaria when given with standard doses of chloroquine. Currently, the only available drug for radical cure is primaquine (PQ) which requires administration over 14 days, resulting in poor compliance. In Indonesia, chloroquine has been replaced by artemisinin-based combination therapy (i.e. ACTs) due to widespread chloroquine resistance. This study will evaluate the efficacy and safety of a single dose of tafenoquine when co-administered with an ACT (i.e. DHA-PQP). This single-center, double-blind, double-dummy, randomized study will test the superiority of DHA-PQP plus TQ against DHA-PQP alone in the prevention of P. vivax malaria relapse at 6 months. The study will be conducted in male Indonesian soldiers diagnosed with P.vivax malaria on return from deployment to a malarious region of Indonesia. A PQ plus DHA-PQP comparator arm is included to provide an informal comparison against the standard 14 day treatment for P.vivax malaria in Indonesia. Subjects who are glucose-6-phosphate dehydrogenase deficient (G6PD deficient) will be excluded due to the risk of acute hemolysis following dosing with 8-aminoquinolines drugs. Subjects who have a recurrence of P.vivax malaria during the study will be treated with an ACT plus PQ (0.5mg/kg for 14 days), in line with local treatment guidelines. At the end of the 6 month follow up period, any subject who has not relapsed will be given open label PQ (0.5mg/kg daily for 14 days) to minimize the likelihood of relapse after the study. Approximately 200 subjects will be screened to achieve 150 randomized subjects. The total duration of study for each subject will be 180-195 days. This study is being carried out to support registration of TQ in Indonesia and other countries where ACTs are first line therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02802501
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 3
Start date	April 8, 2018
Completion date	August 19, 2019

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05096702` - Operational Feasibility of Appropriate Radical Cure of Plasmodium Vivax With Tafenoquine or Primaquine After Quantitative G6PD Testing in Brazil
Recruiting	`NCT05540470` - Radical CUREfor MAlaria Among Highly Mobile and Hard-to-reach Populations in the Guyanese Shield	N/A
Active, not recruiting	`NCT04079621` - Short Course Radical Cure of P. Vivax Malaria in Nepal	Phase 4
Completed	`NCT03307369` - A Retrospective Study of Severe Plasmodium Vivax
Completed	`NCT01213966` - Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection	Phase 2
Completed	`NCT00811096` - Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax	Phase 2
Terminated	`NCT03337152` - Assessing a Risk Model for G6PD Deficiency	Phase 4
Completed	`NCT05753150` - Operational Feasibility of Appropriate Plasmodium Vivax Radical Cure After G6PD Testing in Thailand
Completed	`NCT02751294` - A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution	Phase 1
Recruiting	`NCT05058885` - Plasmodium Vivax Among Duffy Negative Population in Cameroon.
Completed	`NCT03377296` - Study of Controlled Human Plasmodium Vivax Infection	N/A
Completed	`NCT00486694` - Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria	Phase 2
Recruiting	`NCT05788094` - ACT vs CQ With Tafenoquine for P. Vivax Mono-infection	Phase 4
Terminated	`NCT02110784` - Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria	Phase 2
Not yet recruiting	`NCT05690841` - FocaL Mass Drug Administration for Vivax Malaria Elimination	Phase 3
Not yet recruiting	`NCT04739917` - Efficacy of a Synthetic Vaccine Derived From Plasmodium Vivax Circumsporozoite Protein (PvCS) in naïve and Semi-immune Volunteers	Phase 2
Completed	`NCT03208907` - DHA-PQP vs Chloroquine and Primaquine for Radical Cure of Vivax Malaria in Brazil	Phase 3
Completed	`NCT02184637` - A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate	Phase 1
Completed	`NCT01928914` - Tafenoquine Thorough QTc Study in Healthy Subjects	Phase 1
Completed	`NCT01081847` - Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants	Phase 1